Navigation Links
Investigational New Drug Application for 'Fat Melting' Injections Cleared by the FDA

Clinical trial on injection lipolysis treatment to begin soon

NEW YORK, Sept. 4 /PRNewswire-USNewswire/ -- The Aesthetic Surgery Education and Research Foundation (ASERF) announced today that it has received approval from the U.S. Food and Drug Administration to initiate a clinical trial investigating the safety and efficacy of one type of injection lipolysis treatment.

Treatments most properly called injection lipolysis have been commonly associated with the terms mesotherapy or fat dissolving "Lipodissolve." These types of treatments claim to reduce or eliminate unwanted local accumulations of fat, but their ingredients and injection locations and techniques may vary slightly. There is also no standardized, consistent, and accepted injection protocol or chemical formulation, with many formulas being proprietary, and without scientifically valid studies documenting their safety or effectiveness or comparing one another. Injection lipolysis involves the injection of various compounds into the subcutaneous fat, but is not currently approved by the FDA for subcutaneous injection for any purpose.

"We are pleased to finally have the approval to move forward on this important clinical trial," said V. Leroy Young, MD, chief investigator for the study. "This study is long overdue, and will go a long way toward developing more standardized protocols and ultimately improving patient safety in this area."

The study, which was designed and funded by ASERF, will be conducted under FDA supervision and will follow patients for 46 weeks to evaluate the efficacy of one form of injection lipolysis and collect data on local and systemic reactions and any long-term complications. The study will include imaging, biochemical analysis and clinical measurements for objective evaluation of the efficacy and safety of the treatment.

"Although there are clinical reports of significant and positive results, they are all anecdotal, and unfortunately there is currently insufficient scientifically valid evidence to support the long term safety and efficacy of injection lipolysis. We hope that this study will provide the data needed to clarify some of the controversy and confusion surrounding this potentially beneficial treatment. The more we know, the better we will be able to educate and inform our patients, and recommend to them, with confidence, the safest and most effective treatments to provide them with the best results," said Alan H. Gold, MD, president of ASERF.

According to the American Society for Aesthetic Plastic Surgery's 2006 Cosmetic Surgery Statistics, injection lipolysis procedures were performed last year on 28,901 Americans -- six times the number of procedures performed the previous year.


The Aesthetic Surgery Education and Research Foundation (ASERF) is dedicated to directed research and physician education in cosmetic plastic surgery. ASERF helps to ensure the safety and effectiveness of new aesthetic (cosmetic) plastic surgical techniques and technologies by funding scientific research and clinical studies, and helps to make new treatments with proven benefits more widely available to patients who seek to improve their quality of life through aesthetic surgery. ASERF is a charitable organization, the research arm of the Society, 100% of member donations go to clinical research.


The American Society for Aesthetic Plastic Surgery, the leading organization of board-certified plastic surgeons specializing in cosmetic plastic surgery. ASAPS active-member plastic surgeons are certified by the American Board of Plastic Surgery or the Royal College of Physicians and Surgeons of Canada.

SOURCE Aesthetic Surgery Education and Research Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New Drug Application Submitted for Investigational Antibiotic Doripenem
2. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
3. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
4. Novel Investigational Drug May Help American Women Suffering from Breast Pain
5. Novartis files application with FDA for Zometa
6. Morepan to file new drug applications with the USFDA
7. Mini motor for micromedical applications
8. Perfusion bioreactor could enhance stem cell research and application in the future
9. Prostate Cancer Can Be Treated By Application Of LASER Technology
10. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human
11. Venus Remedies Files 5th International Patent Application
Post Your Comments:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, ... at Work award to iHire in recognition of their exemplary accomplishments in worksite health ... annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association (PHA) ... will receive two significant new grants to support its work to advance research ... anniversary by recognizing patients, medical professionals and scientists for their work in fighting ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
(Date:6/23/2016)... -- The Biotechnology industry might still be ... opportunities to investors. assesses the recent performances of ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ... complimentary trade alerts at: ...
(Date:6/23/2016)... Leading BioSciences Inc., a clinical-stage biopharmaceutical ... from a breakdown of the mucosal barrier, today ... as chief executive officer. Mr. Doyle, a ... and board of directors, previously served as chief ... provide continued leadership and strategic direction to the ...
Breaking Medicine Technology: